高危耐药及复发妊娠滋养细胞肿瘤诊疗现状

毛铭懿; 蒋芳; 向阳

doi:10.12290/xhyxzz.2024-0135

高危耐药及复发妊娠滋养细胞肿瘤诊疗现状

doi: 10.12290/xhyxzz.2024-0135

毛铭懿^1,2,
蒋芳¹,
向阳^1, ,

1 中国医学科学院北京协和医院妇产科国家妇产疾病临床研究中心, 北京 100730;
2 中国医学科学院北京协和医学院临床医学专业试点班, 北京 100730

基金项目:

国家重点研发计划（2023YFC2705802）；中央高水平医院临床科研专项（2022-PUMCH-C-058）

详细信息

通讯作者:
向阳,E-mail:XiangY@pumch.cn

中图分类号: R711; R737.3
计量
- 文章访问数: 5
- HTML全文浏览量: 1
- PDF下载量: 1
- 被引次数: 0
出版历程
- 网络出版日期: 2024-04-24

Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia

MAO Mingyi^1,2,
JIANG Fang¹,
XIANG Yang^{1
, ,}

1 National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
2 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National Key R&D Program of China (2023YFC2705802)

摘要

摘要: 妊娠滋养细胞肿瘤（gestational trophoblastic neoplasia，GTN）可根据FIGO临床分期及预后评分系统将患者分为低危和高危两大类，其中高危患者具有较高的单药化疗耐药风险，应首选联合化疗。然而，仍有部分高危患者在联合化疗后出现耐药或在治愈后复发，此类患者异质性强，后续治疗难度大，近年来受到研究者广泛关注。本文就高危耐药及复发GTN患者的危险因素及治疗策略进行综述，以期为早期识别高风险患者及其精准治疗提供依据。
- 妊娠滋养细胞肿瘤 /
- 高危 /
- 耐药 /
- 复发
Abstract: Gestational trophoblastic neoplasia (GTN) can be classified into low-risk and high-risk patients based on the FIGO staging and scoring system. High-risk patients have a higher risk of resistance to single-agent chemotherapy and require combination chemotherapy. However, there are still some high-risk patients who develop resistance to combination chemotherapy or experience recurrence after cure. These patients exhibit strong heterogeneity, and subsequent treatment poses significant challenges, attracting considerable attention in recent years. Therefore, this article provides a review of the risk factors and treatment strategies for high-risk resistant and recurrent GTN patients, aiming to provide a basis for early identification of high-risk patients and their precise treatment.
- Gestational trophoblastic neoplasia /
- High-risk /
- Resistance /
- Recurrence

HTML全文

参考文献(32)

[1]	中国抗癌协会妇科肿瘤专业委员会.妊娠滋养细胞疾病诊断与治疗指南2021年版)[J].中国癌症杂志, 2021, 31(6):520-532.
[2]	Kohorn E. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease:description and critical assessment[J]. International Journal of Gynecologic Cancer, 2001, 11(1).
[3]	Ngan H Y S, Seckl M J, Berkowitz R S, et al. Diagnosis and management of gestational trophoblastic disease:2021 update[J]. Int J Gynaecol Obstet, 2021, 155 Suppl 1(Suppl 1):86-93.
[4]	Escobar P F, Lurain J R, Singh D K, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy[J]. Gynecol Oncol, 2003, 91(3):552-557.
[5]	Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2006, 16(3):1432-1438.
[6]	Li Y, Kong Y, Wan X, et al. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ＞/=5[J]. Oncologist, 2021, 26(12):e2209-e2216.
[7]	Jareemit N, Therasakvichya S, Freitas F, et al. EMACO for treatment of gestational trophoblastic neoplasia:A multinational multicenter study[J]. Gynecol Oncol, 2023, 170:114-122.
[8]	Yang J, Xiang Y, Wan X, et al. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV):A report based on our 10-year clinical experiences[J]. Gynecol Oncol, 2016, 143(1):68-72.
[9]	Kong Y, Zong L, Cheng H, et al. Management and risk factors of recurrent gestational trophoblastic neoplasia:An update from 2004 to 2017[J]. Cancer Med, 2020, 9(7):2590-2599.
[10]	Mao Y, Wan X, Lv W, et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen[J]. Int J Gynaecol Obstet, 2007, 98(1):44-47.
[11]	Lu W G, Ye F, Shen Y M, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia:a clinical analysis of 54 patients[J]. Int J Gynecol Cancer, 2008, 18(2):357-362.
[12]	Wang M, Shen L, Xu X, et al. Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia[J]. BioMed Research International, 2021, 2021:1-8.
[13]	Wang J, Short D, Sebire N J, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)[J]. Ann Oncol, 2008, 19(9):1578-1583.
[14]	Feng F, Xiang Y, Wan X, et al. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia[J]. Ann Oncol, 2011, 22(7):1588-1594.
[15]	Veras E, Kurman R J, Wang T-L, et al. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases[J]. International Journal of Gynecological Pathology, 2017, 36(2):146-153.
[16]	Bolze P A, Patrier S, Massardier J, et al. PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes[J]. Int J Gynecol Cancer, 2017, 27(3):554-561.
[17]	Huang M, Pinto A, Castillo R P, et al. Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma[J]. J Clin Oncol, 2017, 35(27):3172-3174.
[18]	Ghorani E, Kaur B, Fisher R A, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J]. Lancet, 2017, 390(10110):2343-2345.
[19]	You B, Bolze P A, Lotz J P, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy:Cohort B of the TROPHIMMUN phase 2 trial[J]. Gynecol Oncol, 2023, 168:62-67.
[20]	Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01):a single-arm, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(11):1609-1617.
[21]	Wang X, Cang W, Liu X, et al. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia:a multicenter, retrospective study[J]. EClinicalMedicine, 2023, 59:101974-101974.
[22]	Hennah L, Seckl M, Ghorani E. Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy[J]. Int J Gynecol Cancer, 2023, 33(3):414-419.
[23]	Doumplis D, Al-Khatib K, Sieunarine K, et al. Short communication:A review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006[J]. BJOG:An International Journal of Obstetrics& Gynaecology, 2007, 114(9):1168-1171.
[24]	Fang J, Wang S, Han X, et al. Role of adjuvant hysterectomy in management of high-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2012, 22(3):509-514.
[25]	Sugrue R, Foley O, Elias K M, et al. Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease[J]. Gynecol Oncol, 2021, 160(2):445-449.
[26]	Feng F, Xiang Y, Li L, et al. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia[J]. Gynecol Oncol, 2009, 113(3):312-315.
[27]	Cao Y, Xiang Y, Feng F, et al. Surgical Resection in the Management of Pulmonary Metastatic Disease of Gestational Trophoblastic Neoplasia[J]. International Journal of Gynecological Cancer, 2009, 19(4):798-801.
[28]	Kanis M J, Lurain J R. Pulmonary Resection in the Management of High-Risk Gestational Trophoblastic Neoplasia[J]. Int J Gynecol Cancer, 2016, 26(4):796-800.
[29]	Zhao L, Qin Y, Ma D, et al. Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia:A retrospective study[J]. Gynecol Oncol, 2022, 167(1):37-41.
[30]	Kong Y, Wang W, Lin J, et al. Management and Predictors of Treatment Failure in Patients with Chemo-Resistant/Relapsed Gestational Trophoblastic Neoplasia with Lung Metastasis[J]. J Clin Med, 2022, 11(24).
[31]	Manchana T, Ittiwut C, Mutirangura A, et al. Targeted therapies for rare gynaecological cancers[J]. Lancet Oncol, 2010, 11(7):685-693.
[32]	Worley M J, Jr., Elias K M, Horowitz N S, et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab:A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute[J]. Gynecol Oncol, 2018, 148(1):5-11.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 5
HTML全文浏览量: 1
PDF下载量: 1
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

高危耐药及复发妊娠滋养细胞肿瘤诊疗现状

doi: 10.12290/xhyxzz.2024-0135

通讯作者:
向阳,E-mail:XiangY@pumch.cn

计量

Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia

计量

目录

留言板

高危耐药及复发妊娠滋养细胞肿瘤诊疗现状

doi: 10.12290/xhyxzz.2024-0135

通讯作者: 向阳,E-mail:XiangY@pumch.cn

计量

出版历程

Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia

计量

出版历程

目录

通讯作者:
向阳,E-mail:XiangY@pumch.cn